Coronary Revascularization (Surgical or Percutaneous) Decreases Mortality After the First Year in Diabetic Subjects but not in Nondiabetic Subjects With Multivessel Disease

Paulo R. Soares(Universidade de São Paulo), José Antônio Franchini Ramires(Universidade de São Paulo), Pedro A. Lemos(Johns Hopkins University), Sérgio Almeida de Oliveira(Federal Center for Technological Education Celso Suckow da Fonseca), Neuza Lopes(Universidade de São Paulo), Luı́z Antonio Machado César(Universidade de São Paulo), Eulógio E. Martinez(Universidade de São Paulo), Whady Hueb(Universidade de São Paulo)

Circulation

July 4, 2006

10.1161/circulationaha.105.000679

Cited by 55

Related Papers

Transfusion Requirements After Cardiac Surgery

|JAMA|2010|1k

Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

|The Lancet|2018|793

Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials

|The Lancet|2009|746

Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data

|The Lancet|2018|733

Five-Year Follow-Up of the Medicine, Angioplasty, or Surgery Study (MASS II)

|Circulation|2007|582